The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The primary goal of the collaboration is joint research into trending and next-generation molecules
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The new facility is expected to generate 500-600 new jobs in the region
The FDA aims to make a decision by April 8, 2026
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Subscribe To Our Newsletter & Stay Updated
